ALLOAllogene Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Allogene Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLO본 종목 | $645M#1 | — | 2.3x#4 | — | -100.0%#5 | 25.9%#2 | — | -68.4%#5 | — | — | 51.4%#4 | — |
| PRME | — | — | — | — | 55.3%#3 | -2.7%#5 | -4498.1%#4 | -262.2%#7 | — | — | -22.1%#7 | — |
| FDMT | — | — | — | — | 230194.6%#1 | 12.9%#4 | -187.2%#3 | -31.0%#3 | — | — | 126.7%#2 | — |
| TECX | $530M#2 | — | 2.3x#3 | — | — | -27.9%#7 | — | -32181.2%#9 | -986.0%#1 | — | 26.2%#5 | — |
| ZURA | $515M#3 | — | 5.1x#5 | — | — | -31.0%#8 | — | -67.6%#4 | — | — | 288.9%#1 | — |
| RGNX | $500M#4 | — | 23.7x#6 | 2.9x#2 | 104.5%#2 | 14.6%#3 | -94.6%#1 | -919.6%#8 | — | — | 13.9%#6 | — |
| EIKN | $499M#5 | — | 0.9x#1 | — | — | — | — | 0.0%#1 | — | — | — | — |
| DNA | $499M#6 | — | 1.1x#2 | 2.9x#1 | -25.1%#4 | 42.8%#1 | -185.3%#2 | -0.1%#2 | — | — | -38.2%#8 | — |
| KYTX | — | — | — | — | — | -26.5%#6 | — | -82.5%#6 | — | — | 103.3%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-08-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice